Varsha Kontham Kulangara, Nagarkatti Mitzi, Nagarkatti Prakash
Department of Pathology, Microbiology and Immunology, School of Medicine, University of South Carolina, Columbia, SC, United States.
Adv Drug Alcohol Res. 2022;2. doi: 10.3389/adar.2022.10550. Epub 2022 Jul 14.
Cannabinoids and the endocannabinoid system have been well established to play a crucial role in the regulation of the immune response. Also, emerging data from numerous investigations unravel the imperative role of gut microbiota and their metabolites in the maintenance of immune homeostasis and gut barrier integrity. In this review, we concisely report the immunosuppressive mechanisms triggered by cannabinoids, and how they are closely associated with the alterations in the gut microbiome and metabolome following exposure to endogenous or exogenous cannabinoids. We discuss how cannabinoid-mediated induction of microbial secondary bile acids, short chain fatty acids, and indole metabolites, produced in the gut, can suppress inflammation even in distal organs. While clearly, more clinical studies are necessary to establish the cross talk between exo- or endocannabinoid system with the gut microbiome and the immune system, the current evidence opens a new avenue of cannabinoid-gut-microbiota-based therapeutics to regulate immunological disorders.
大麻素和内源性大麻素系统在免疫反应调节中发挥关键作用,这一点已得到充分证实。此外,众多研究的新数据揭示了肠道微生物群及其代谢产物在维持免疫稳态和肠道屏障完整性方面的重要作用。在本综述中,我们简要报告大麻素引发的免疫抑制机制,以及它们如何与内源性或外源性大麻素暴露后肠道微生物组和代谢组的变化密切相关。我们讨论了肠道中由大麻素介导诱导产生的微生物次级胆汁酸、短链脂肪酸和吲哚代谢产物如何即使在远端器官也能抑制炎症。虽然显然需要更多临床研究来确定外源性或内源性大麻素系统与肠道微生物组和免疫系统之间的相互作用,但目前的证据为基于大麻素-肠道微生物群的疗法调节免疫紊乱开辟了一条新途径。